Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-11-21
2006-11-21
Ulm, John (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388220
Reexamination Certificate
active
07138117
ABSTRACT:
The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 4 (CCR4) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR4 with a ligand thereof, and to use of the antibodies and fragments in research, therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 5440021 (1995-08-01), Chuntharapai et al.
patent: 5543503 (1996-08-01), Chuntharapai et al.
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 5932703 (1999-08-01), Godiska et al.
patent: 6084075 (2000-07-01), Lind et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6245332 (2001-06-01), Butcher et al.
patent: 2002/0160015 (2002-10-01), Wells et al.
patent: 0 860 446 (1998-08-01), None
patent: 11-243960 (1999-09-01), None
patent: WO 95/08576 (1995-05-01), None
patent: WO 96/23068 (1996-08-01), None
patent: WO 98/27815 (1998-07-01), None
patent: WO 98/44953 (1998-10-01), None
patent: WO 99/15666 (1999-04-01), None
Frade, J.M.R., et al., “Characterization of the CCR2 Chemokine Receptor: Functional CCR2 Receptor Expression in B Cells”,J. of Immunology, 159:5576-5584 (1997).
Wu, L., et al., “Discrete Steps in Binding and Signaling of Interleukin-8 with Its Receptor”,The Journal of Biological Chemistry, 271(49): 31202-31209 (1996).
Wu, L., et al., “Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding”,J. Exp. Med., 186(8): 1373-1381 (1997).
Meyer, A., et al., “Cloning and Characterization of a Novel Murine Macrophage Inflammatory Protein-1α Receptor,”The Journal of Biological Chemistry, 271(24) :14445-14451 (1996).
Imai, T., et al., “Macrophage-Derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4,”The Journal of Biological Chemistry, 272(3) :1764-1768 (1998).
Imai, T., et al., “The T Cell-Directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4,”The Journal of Biological Chemistry, 272(23) :15036-15042 (1997).
Bonecchi, R., et al., “Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s,”J. Exp. Med., 187(1): 129-134 (1998).
Dürig, J., et al., “Expression of Macrophage Inflammatory Protein-1α Receptors in Human CD34+Hematopoietic Cells and Their Modulation by Tumor Necrosis Factor-α and Interferon-γ,”Blood, 92(9) :3073-3081 (1998).
Catalog of Santa Cruz Biotechnology, Inc., Research Antibodies 97/98, pp. 319-320 (1997).
Power, C.A., et al., “Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor and cDNA from a Human Básophilic Cell Line,”The Journal of Biological Chemisty, 270(33) :19495-19500 (1995).
Youn, B-S., et al., “Molecular Cloning and Characterization of a cDNA, CHEMR1, Encoding a Chemokine Receptor with a Homology to the Human C-C Chemokine Receptor, CCR-4,”Blood, 89 (12) :4448-4460 (1997).
GenBank Accession No.: X94151, Jul. 4, 1996 NCB1 [online]. [retrieved on Feb. 11, 1999] Retrieved from the Internet, <URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retreive+db=nucleotide+list—uids. . . . >.
Genebank Accession No.: X85740, Jun. 4, 1996 NCB1 [online]. [retrieved on Feb. 11, 1999] Retrieved from the Internet, <URL:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retreive+db=nucleotide+list—uids:. . . >.
Förster, R. et al., “A general method for screening mABs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1- transfected 293 cells and solid-phase cell ELISA,”Biochemical and Biophysical Research Communications, 196(3) :1496-1503 (1993).
Andrew, D.P. et al., “STCP-1 (MDC) CC Chemokine Acts Specifically on Chronically Activated Th2 Lyphocytes and Is Produced by Monocytes on Stimulation with Th2 Cytokines IL-4 and IL-13,”The Journal of Immunology, 161:5027-5038 (1998).
Sallusto, F. et al., “Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes,”J. Exp. Med., 187(6) :875-883 (1998).
Ponath, P.D., “Chemokine receptor antagonists: novel therapeutics for inflammation and AIDS,”Exp. Opin. Invest. Drugs, 7(1):1-18 (1998).
Yoneyama, H., et al., “Pivotal Role of TARC, a CC Chemokine in Bacteria-Induced Fulminant Hepatic Failure in Mice,”J. Clin. Invest., 102(11) :1933-1941 (1998).
Heath, H., et al., “Chemokine Receptor Usage by Human Eosinophils-The Importance of CCR3 Demonstrated Using an Antagonistic Monoclonal Antibody,”J. Clin. Invest., 99(2) :178-184 (1997).
Campbell, J.J., et al., “The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells,”Nature, 400:776-780 (1999).
XP002138299, Abstract No. 1999-603709[52], (abstract of Japanese Patent No. JP11243960).
Chuntharapai, A., et al., “Generation of Monoclonal Antibodies to Chemokine Receptors,”Methods in Enzymology, 288:15-27 (1997).
Thompson, S.D., et al., “Chemokine Receptor CCR4 and CD4+T Cells in Juvenile Rheumatoid Arthritis Synovial Fluid Defines a Subset of Cells with Increased IL-4: IFN-γ mRNA Ratios,”J. Immunology, 166:6899-6906 (2001).
Panina-Bordignon, P., et al., “The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics,”J. Clin. Invest., 107:1357-1364 (2001).
Chvatchko, Y., et al., “A Key Role for CC Chemokine Receptor 4 in Lipopolysaccharide induced Endotoxic Shock,”J. Exp. Med., 191:1755-1763 (2000).
Inngjerdingen, M., et al., “Human NK Cells Express CC Chemokine Receptors 4 and 8 and Respond to Thymus and Activation-Regulated Chemokine, Macrophage-Derived Chemokine, and I-309,”J. Immunol., 164:4048-4054 (2000).
Mackay, C. R., “Chemokines: immunology's high impact factors,”Nature Immunology, 2:95-101 (2001).
Andrew David P.
Ruffing-Graham Nancy
Wu Lijun
Hamilton Brook Smith & Reynolds P.C.
Millennium Pharmaceuticals Inc.
Ulm John
LandOfFree
Anti-CCR4 antibodies and methods of use therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-CCR4 antibodies and methods of use therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CCR4 antibodies and methods of use therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3646194